31 Oct 2024
Hemogenyx Pharmaceuticals non-confidential investor presentation – October 2024
Investors
Company Information
The Company was incorporated and registered in England and Wales on 13 February 2013 as a private limited company and re-registered on 25 November 2014 as a public limited company. The Company’s wholly owned US operating subsidiary, Hemogenyx Pharmaceuticals LLC, is incorporated in the state of Delaware.
Registered Office
6th Floor, 60 Gracechurch Street, London, EC3V 0HR, United Kingdom
Company registered in England & Wales, No. 08401609
Employee Incentive Plan
The 2021 Employee Incentive Plan approved by the Board of Directors on 27 July 2021 and by the shareholders at the annual general meeting of 30 June 2022
Prospectuses
The Prospectus for the investment in Hemogenyx Pharmaceuticals by Mint Capital published on 29 January 2021
A Supplementary Prospectus was published on 12 May 2021 following publication of the Company’s annual report for 2020
The Prospectus for Hemogenyx Pharmaceuticals upon admission to the LSE on 5th October 2017
Documents re. the acquisition of Hemogenyx Pharmaceuticals plc by Silver Falcon plc
Corporate Governance
The Company observes the requirements of the UK Corporate Governance Code. The Company is in compliance with the UK Corporate Governance Code, save as set out below:
Each of the Directors has been briefed on their obligations and has signed up to a protocol relating to the management and dissemination of confidential information so as to ensure that the Company and its Directors comply with the provisions of the Market Abuse Regulation and the requirement to ensure that any inside information and other confidential information remains properly collated, recorded and held confidential.
The Company has established audit, remuneration and nomination committees.
Audit Committee
The Audit Committee has responsibility for, among other things, the monitoring of the integrity of the financial statements of the Company and its Enlarged Group and the involvement of the Group’s auditors in that process. It focuses in particular on compliance with accounting policies and ensuring that an effective system of external audit and financial control is maintained, including considering the scope of the annual audit and the extent of the non-audit work undertaken by external auditors and advising on the appointment of external auditors. The ultimate responsibility for reviewing and approving the annual report and accounts and the half-yearly reports remains with the Board. The Audit Committee will meet at least three times a year at the appropriate times in the financial reporting and audit cycle.
The members of the Audit Committee are Peter Redmond, who acts as chairman of the committee, and Professor Sir Marc Feldmann, and the Financial Controller attends its meetings.
Remuneration Committee
The remuneration committee reviews the performance of the executive directors and makes recommendations to the Board on matters relating to their remuneration and terms of employment. The committee also makes recommendations to the Board on proposals for the granting of share awards and other equity incentives pursuant to any share award scheme or equity incentive scheme in operation from time to time. The Remuneration Committee meets at least twice a year.
The members of the Remuneration Committee are Peter Redmond, who acts as chairman of the committee, and Alexis Sandler.
Nomination Committee
The Nomination Committee is responsible for considering and making recommendations to the Board in respect of appointments to the Board, the Board committees and the chairmanship of the Board committees. It is also responsible for keeping the structure, size and composition of the Board under regular review, and for making recommendations to the Board with regard to any changes necessary, taking into account the skills and expertise that will be needed on the Board in the future. The Nomination Committee meets at least once a year.
The members of the Nomination Committee are Peter Redmond, Alexis Sandler, Peter and Professor Sir Marc Feldmann.
Corporate Advisers
The Company observes the requirements of the UK Corporate Governance Code. The Company is in compliance with the UK Corporate Governance Code, save as set out below:
Each of the Directors has been briefed on their obligations and has signed up to a protocol relating to the management and dissemination of confidential information so as to ensure that the Company and its Directors comply with the provisions of the Market Abuse Regulation and the requirement to ensure that any inside information and other confidential information remains properly collated, recorded and held confidential.
Registered Office
6th Floor
60 Gracechurch Street
London
EC3V 0HR
United Kingdom
Registrar
Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol
BS13 8AE
Joint Broker
SP Angel Corporate Finance LLP
35 Maddox St
Mayfair
London
W1S 2PP
Legal Advisers
To The Company
As To English Law
Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS
Joint Broker
Peterhouse Capital Limited
80 Cheapside
London
EC2V 6EE
Legal Advisers
To The Company
As To US Law
Rubin & Rudman LLP
50 Rowes Wharf
Boston
Massachusetts 0211
Cooley LLP
500 Boylston Street
Boston, MA 02116-3736
Auditors And Reporting
Accountants
PKF Littlejohn LLP
Westferry Circus
Canary Wharf
London
E14 4HD
Shareholder Information
Shares Issued
As at 6 March 2024, the number of shares in issue was 1,341,815,988.
AS AT 6 MARCH 2024
Significant Shareholders
None known at present time except for Director shareholdings
AS AT 6 MARCH 2024
Director Shareholdings
AS AT 6 MARCH 2024
| DIRECTOR | NUMBER | ORDINARY SHARES % |
|---|---|---|
| Alexis Sandler | 75,090,685 | 5.60 |
| Dr Vladislav Sandler | 41,544,677 | 3.10 |
| Peter Redmond | 5,596,270 | 0.42 |
Shares Not In Public Hands
Insofar as it is aware, as at 6 March 2024, 14.25% of the Company’s securities were not in public hands.
AS AT 6 MARCH 2024
UK City Code On Takeovers And Mergers
The Company is subject to the provisions of the City Code on Takeovers and Mergers.
Shareholder Circulars
Annual and Half Year Reports, together with historical general meeting notices, blank proxy voting forms, and other shareholder circulars
Most rated shareholder circular:
8 JUNE 2021
Notice of Annual General Meeting to be held on 30 June 2022 and 2021 Equity Incentive Plan with Non-Employee Sub-Plan proposed for approval at the AGM
Other Exchanges And Trading Platforms
Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.
Share Data
Read about the Company’s share price, trading data and other technical information on our shares
Profile
Hemogenyx Pharmaceuticals (HEMO)
SECTOR Pharmaceuticals & Biotech
Minimum 15 minutes delayed
Company Listing Data
| EPIC | HEMO |
| SECTOR | Pharmaceuticals & Biotech |
| SEDOL | BYX3WZ2 |
| ISIN | GB00BYX3WZ24 |
| Market Sector | Main Market |
| Market Segment | SSQ3 |
| Country of register | UK |
| Currency | British Pence |
| Date listed | 22 December 2014 |
Annual & half-year reports
The most recent presentation is at the top; scroll down the page for any prior materials.